skip to content

Chan, Richard Kok Tiong

CPSO#: 68551

MEMBER STATUS
Active Member as of 01 Oct 2018
CURRENT OR PAST CPSO REGISTRATION CLASS
Restricted as of 23 Apr 2018

Summary

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum ac diam sit amet quam vehicula elementum sed sit amet dui. Vivamus suscipit tortor eget felis porttitor volutpat. Curabitur non nulla sit amet nisl tempus convallis quis ac lectus. Curabitur aliquet quam id dui posuere blandit. Vivamus suscipit tortor eget felis porttitor volutpat. Curabitur arcu erat, accumsan id imperdiet et, porttitor at sem. Vestibulum ac diam sit amet quam vehicula elementum sed sit amet dui. Donec sollicitudin molestie malesuada. Pellentesque in ipsum id orci porta dapibus.

Former Name: No Former Name

Gender: Male

Languages Spoken: Chinese, English

Education: National University of Singapore, 1986

Practice Information

Primary Location of Practice
LHSC - University Campus Site
Department of Clinical
Neurological Science
339 Windermere Rd PO Box 5339
London ON  N6A 5A5
Phone: (519) 663-3292
Fax: (519) 663-3294 Electoral District: 02

Hospital Privileges

Hospital Location
London Health Sciences Centre London
London Health Sciences Centre Victoria Hospital London
St Joseph's Health Care, London London
St Joseph's Health Care,London - Parkwood Hospital London

Specialties

Specialty Issued On Type
Neurology Effective:19 May 2006 RCPSC Specialist

Postgraduate Training

Please note: This information may not be a complete record of postgraduate training.



Schulich School of Medicine and Dentistr, 01 Jul 1994 to 30 Jun 1995
CF - Neurology

Schulich School of Medicine and Dentistr, 01 Jul 1995 to 30 Jun 1996
CF - Neurology

Schulich School of Medicine and Dentistr, 01 Jul 1996 to 30 Jun 1997
CF - Neurology

Registration History

Action Issue Date
First certificate of registration issued: Postgraduate Education Certificate Effective: 09 Sep 1994
Expired: Terms and conditions of certificate of registration Expiry: 08 Sep 1996
Subsequent certificate of registration issued: Restricted certificate Effective: 18 Sep 1996
Expired: Terms and conditions imposed on certificate by Registration Committee Effective: 30 Jun 1997
Subsequent certificate of registration Issued: Academic Practice Certificate Effective: 01 Jan 2004
Expired: Terms and conditions imposed on certificate by Registration Committee Effective: 28 Jun 2013
Subsequent certificate of registration Issued: Independent Practice Certificate Effective: 28 Jun 2013
Transfer of class of certificate to: Restricted certificate Effective: 23 Apr 2018
Terms and conditions imposed on certificate by Discipline Committee Effective: 23 Apr 2018
Suspension of registration imposed: Discipline Committee Effective: 01 May 2018
Suspension of registration removed Effective: 01 Oct 2018

Practice Restrictions

Imposed By Effective Date Expiry Date Status
Discipline Committee Effective: 23 Apr 2018 Active
             As from 3:30 p.m., April 23, 2018, by order of the Discipline Committee of the
            College of Physicians and Surgeons of Ontario, the following terms, conditions
            and limitations are imposed on the certificate of registration held by Dr.
            Richard Kok Tiong Chan:

            Prescribing Privileges 

            (1)   Dr. Chan shall issue new prescriptions or renew existing prescriptions
                  for any of the following substances only to patients whom Dr. Chan is
                  treating in a hospital setting (including in-patients, clinic patients,
                  and emergency department patients):

                  (a)   Narcotic Drugs (from the Narcotic Control Regulations made under
                        the Controlled Drugs and Substances Act, S.C., 1996, c. 19); and 
                  
                  (b)   Narcotic Preparations (from the Narcotic Control Regulations made
                        under the Controlled Drugs and Substances Act, S.C., 1996, c. 19).
                  
                  A summary of the above-named drugs [from Appendix I to the Compendium of
                  Pharmaceuticals and Specialties] is attached hereto as Schedule "A"; and
                  the current regulatory lists are attached hereto as Schedule "B".
                  
            Prescription Log

             (2)  Dr. Chan shall record all prescriptions he writes for the substances set
                  out in paragraph 4.(1), and other specified information, in a
                  prescription log or logs containing the information set out in the
                  attached Schedule "C", which shall be made available to the College at
                  the College's request. A copy of each prescription written by Dr. Chan
                  for a drug set out in paragraph 4.(1) shall be maintained either in the
                  appropriate hospital records or Dr. Chan's office chart.  

            Coursework

             (3)  At his own expense, Dr. Chan shall participate in and successfully
                  complete by the end of 2018: 

                  (a)   A prescribing course acceptable to the College; and  
                  
                  (b)   The PROBE course in ethics and professionalism by obtaining an
                        unconditional pass, or any alternate course in ethics and
                        professionalism approved by the College. Dr. Chan will agree to
                        abide by any recommendations of the PROBE program and provide proof
                        of completion to the College. 
                  
            Compliance

            (4)   Dr. Chan must inform the College of each and every location at which he
                  practices or has privileges, including, but not limited to, hospital(s),
                  clinic(s) and office(s), in any jurisdiction (collectively the "Practice
                  Location(s)"), within fifteen (15) days of commencing practice at that
                  location.

            (5)   Dr. Chan shall be solely responsible for payment of all fees, costs,
                  charges, expenses, etc. arising from the implementation of any of the
                  terms of this Order. 

            (6)   Dr. Chan shall co-operate with unannounced inspections of his Practice
                  Location(s) and patient charts by the College and to any other activity
                  the College deems necessary in order to monitor his compliance with the
                  terms of this Order. 

            (7)   Dr. Chan shall provide his irrevocable consent to the College to make
                  appropriate enquiries of the Ontario Health Insurance Plan ("OHIP"), the
                  Drug Program Services Branch, the Narcotics Monitoring System ("NMS")
                  implemented under the Narcotics Safety and Awareness Act, 2010 and any
                  person or institution that may have relevant information, in order for
                  the College to monitor his compliance with the terms of this Order. 

            (8)   The College may provide this Order to any Chief(s) of Staff, or a
                  colleague with similar responsibilities, at any Practice Location where
                  he practices or has privileges ("Chief(s) of Staff"), or other person or
                  individual as necessary for the implementation of this Order and shall
                  consent to the College providing to said Chief(s) of Staff, person or
                  organization with any information the College has that led to this Order
                  and/or any information arising from the monitoring of his compliance with
                  this Order.

Previous Hearings

Committee: Discipline
Decision Date: 23 Apr 2018
Summary:

On April 23, 2018, the Discipline Committee found that Dr. Richard Kok Tiong Chan committed an act of professional misconduct, in that he has engaged in conduct or an act or omission relevant to the practice of medicine that, having regard to all of the circumstances, would reasonably be regarded by members as unprofessional.

Dr. Richard Kok Tiong Chan (“Dr. Chan”) is a neurologist with the Department of Clinical Neurological Sciences, London Health Sciences Centre.


Between 2011 and 2015, Dr. Chan on numerous occasions prescribed Fentanyl patches to his relative (Relative 1) who lives abroad. On each of these prescriptions the ID of the relative was her passport number and the address was Dr. Chan’s home address. Dr. Chan prescribed to another relative (Relative 2) who also lives abroad. In July 18, 2014, this relative filled a prescription, which was written by Dr. Chan, for 150 tabs of hydromorphone. The prescription bore this relative’s passport number, and indicated her address to be Dr. Chan’s home address.

Dr. Chan went personally to the drug store himself to have each of the prescriptions he wrote for both of his relatives filled. The Fentanyl patches he prescribed to Relative 1 and the hydromorphone tabs he prescribed to Relative 2were provided to him by the pharmacy.

On January 13, 2016, Dr. Chan wrote a prescription for Relative 1 for 180 Fentanyl patches. As with the previous prescriptions, it bore her passport number and indicated her address to be Dr. Chan’s home address. On the prescription he submitted to the Shoppers Drug Mart (“SDM”) pharmacy, Dr. Chan wrote “Patient leaving town, OK to release all supplies now”.

When in January, 2016, the SDM pharmacist telephoned a number believed to be for the patient, Dr. Chan answered the pharmacist’s call and confirmed that he was the prescribing physician, and that he had written the prescription for Relative 1. The pharmacist advised Dr. Chan that the prescription he had written would not be filled because it was for his relative. In a separate conversation with the pharmacy owner, it was suggested to Dr. Chan that he have the patient’s family physician write the prescription.


Several days later, Dr. Chan asked Dr. X, a clinical fellow working under his supervision, to write a prescription for Fentanyl for Relative 1. Dr. Chan approached Dr. X during clinic hours and when she was between patients, he told her that his relative had been using the medication and he had been prescribing to her for years. Dr. Chan also told Dr. X that he would have asked another colleague to write the prescription, but that there were no other staff doctors around and that he needed it right away. He told her what medication to prescribe, and he specified the dose and quantity. Dr. Chan told Dr. X that he had already presented a prescription for Fentanyl to the pharmacy, but the pharmacy requested that he have another physician issue the prescription.

Dr. X did not assess Dr. Chan’s relative. She did not feel she could refuse Dr. Chan’s request, as Dr. Chan was her supervisor and wrote the prescription as requested by Dr. Chan. The same day Dr. Chan submitted the prescription written by Dr. X to the SDM pharmacy to be filled. The pharmacy did not fill the prescription written by Dr. X.


Over January 18 and 19, 2016, Drs. Chan and X exchanged the text wherein Dr. Chan wrote Dr. X that he ended up not sending the prescription to the pharmacy as the pharmacy returned the stocks, that he is glad that he didn’t have to use it as he feels awkward for asking her to write the script, and stated that he will bring his relative to the doctor when he gets home. Several days later, the pharmacy telephoned Dr. X to confirm whether the prescription she had written was valid. Dr. X confirmed having written it, but stated that she had not seen the patient.

In the course of the College’s investigation into Dr. Chan’s prescribing, Dr. Chan provided conflicting or inaccurate information regarding:

- Dr. Chan’s contact with a physician who treated Dr. Chan’s Relative 1in the foreign country where she resides;
- The length of time for which he had been prescribing Fentanyl to Relative 1;
- The number of pharmacies at which he had filled Relative 1’s Fentanyl prescriptions;
- Where and how he treated and examined Relative 1; and
- How he got the Fentanyl to Relative 1.

 
In the course of the College’s investigation into Dr. Chan’s prescribing, Dr. Chan provided some information that conflicted with information provided to the College by the pharmacist and/or pharmacy owner.

Disposition

On April 23, 2018, the Committee ordered and directed that:

- the Registrar suspend Dr. Chan’s certificate of registration for a five (5) month period, to commence at 12:01 a.m. on May 1, 2018.

- the Registrar to impose the following terms, conditions and limitations on Dr. Chan’s certificate of registration:

Prescribing Privileges
- Dr. Chan shall issue new prescriptions or renew existing prescriptions for any of the following substances only to patients whom Dr. Chan is treating in a hospital setting (including in-patients, clinic patients, and emergency department patients):
- Narcotic Drugs (from the Narcotic Control Regulations made under the Controlled Drugs and Substances Act, S.C., 1996, c. 19); and
- Narcotic Preparations (from the Narcotic Control Regulations made under the Controlled Drugs and Substances Act, S.C., 1996, c. 19).
A summary of the above-named drugs [from Appendix I to the Compendium of Pharmaceuticals and Specialties] is attached as Schedule “A” to the Order dated April 23, 2018; and the current regulatory lists are attached as Schedule “B” to the Order dated April 23, 2018.

Prescription Log
- Dr. Chan shall record all prescriptions he writes for the substances set out in paragraph 4.(1), and other specified information, in a prescription log or logs containing the information set out in the attached Schedule “C” to the Order Dated April 23, 2018, which shall be made available to the College at the College’s request. A copy of each prescription written by Dr. Chan for a drug set out in paragraph 4(1) shall be maintained either in the appropriate hospital records or Dr. Chan’s office chart.

Coursework
- At his own expense, Dr. Chan shall participate in and successfully complete by the end of 2018:
- A prescribing course acceptable to the College; and
- The PROBE course in ethics and professionalism by obtaining an unconditional pass, or any alternate course in ethics and professionalism approved by the College. Dr. Chan will agree to abide by any recommendations of the PROBE program and provide proof of completion to the College.

Compliance
- Dr. Chan must inform the College of each and every location at which he practices or has privileges, including, but not limited to, hospital(s), clinic(s) and office(s), in any jurisdiction (collectively the "Practice Location(s)"), within fifteen (15) days of commencing practice at that location.
- Dr. Chan shall be solely responsible for payment of all fees, costs, charges, expenses, etc. arising from the implementation of any of the terms of this Order.
- Dr. Chan shall co-operate with unannounced inspections of his Practice Location(s) and patient charts by the College and to any other activity the College deems necessary in order to monitor his compliance with the terms of this Order.
- Dr. Chan shall provide his irrevocable consent to the College to make appropriate enquiries of the Ontario Health Insurance Plan ("OHIP"), the Drug Program Services Branch, the Narcotics Monitoring System ("NMS") implemented under the Narcotics Safety and Awareness Act, 2010 and any person or institution that may have relevant information, in order for the College to monitor his compliance with the terms of this Order.
- The College may provide this Order to any Chief(s) of Staff, or a colleague with similar responsibilities, at any Practice Location where he practices or has ("Chief(s) of Staff"), or other person or individual as necessary for the implementation of this Order and shall consent to privileges the College providing to said Chief(s) of Staff, person or organization with any information the College has that led to this Order and/or any information arising from the monitoring of his compliance with this Order.


- Dr. Chan appear before the panel to be reprimanded.

- Dr. Chan pay to the College its costs of this proceeding in the amount of $6,000 within thirty (30) days from the date of this Order.


Decision: Download Full Decision (PDF)
Hearing Date(s): April 23, 2018